#Global Trends – Page 20 – HEALTHCARE INSIGHTS

Key Development American biopharmaceutical major Gilead Sciences, Inc. (NASDAQ: GILD) officially released its Q2 2026 financial readouts, generating total quarterly... Read more

Tag: #Global Trends

Greater China Commercial Expansion: Innovent Biologics and Daiichi Sankyo Sign Exclusive Commercialization Agreement for Vanflyta® in China

Rare Oncology Licensing Agreement: Sobi Secures Global Rights to Innate Pharma’s Lacutamab in Up to $580 Million Deal Targeting Cutaneous T-Cell Lymphoma (CTCL)

Biopharma AI Convergence: Novo Nordisk and Amazon Web Services (AWS) Form Strategic AI Drug Discovery Pact, Launching London Innovation Hub

Cross-Border Food Safety Crisis: Taylor Farms Issues Voluntary Recall of Salsa and Guacamole Formulations Over Imported Jalapeño Salmonella Risk

Historic Vaccine Milestone: US FDA Grants Approval for Moderna’s mFLUSIVA® – The World’s First mRNA-Based Seasonal Influenza Vaccine

Outbreak Diagnostic Response: Roche Launches Two Novel PCR Cyclospora Test Panels as U.S. Foodborne Outbreak Escalates to Record Levels

HIV & PrEP Commercial Acceleration: Gilead Sciences Outperforms Q2 2026 Revenue Estimates at $7.8 Billion, Offsetting One-Time M&A Charges

Anti-Obesity Franchise Market Dynamics: Novo Nordisk Raises 2026 Outlook, Yet Shares Fall 6% as Oral Wegovy Sales Miss Consensus and CagriSema Trial Disappoints

Post-COVID Restructuring Matrix: Pfizer Beats Q2 2026 Earnings Expectations, Targets Additional $2.5 Billion Cost Cuts, and Shifts M&A Strategy to Bolt-On Deals

Facebook

Map

Online Members